NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT00001019

Locations: 🇺🇸
St Louis Univ School of Medicine, St Louis, Missouri, United States
🇺🇸
Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Vanderbilt Univ Hosp, Nashville, Tennessee, United States

and more 1 locations

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 14

Registration Number: NCT00000749

Locations: 🇺🇸
Vanderbilt Univ Hosp, Nashville, Tennessee, United States
🇺🇸
Univ of Washington / Pacific Med Ctr, Seattle, Washington, United States

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

Not Applicable

Completed

Conditions: Toxoplasmosis, Cerebral
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 600

Registration Number: NCT00000666

Locations: 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
Community Consortium of San Francisco, San Francisco, California, United States
🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States

and more 13 locations

Outcomes of Anti-HIV Therapy During Early HIV Infection

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT00001093

Locations: 🇺🇸
San Francisco Gen Hosp / UCSF AIDS Program, San Francisco, California, United States
🇺🇸
UCSD, San Diego, California, United States
🇺🇸
Cedars Sinai Med Ctr, Los Angeles, California, United States

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

Not Applicable

Completed

Conditions: Mycobacterium Avium-intracellulare Infection
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 636

Registration Number: NCT00000883

Locations: 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Cook County Hosp, Chicago, Illinois, United States
🇺🇸
Emory Univ, Atlanta, Georgia, United States

and more 48 locations

The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS

Not Applicable

Completed

Conditions: HIV Infections
Pneumonia, Pneumocystis Carinii

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT00000717

Locations: 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States

and more 4 locations

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-10-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT00001000

Locations: 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States

A Study of Azidothymidine in HIV-Infected Children

Phase 2

Completed

Conditions: Encephalopathies
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT00000982

Locations: 🇺🇸
Walter Reed / USUHS / Pediatrics, Bethesda, Maryland, United States
🇺🇸
Children's Hosp at Albany Med Ctr, Albany, New York, United States
🇺🇸
Univ of Florida Med Ctr, Jacksonville, Florida, United States

and more 4 locations

A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT00000716

Locations: 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States

and more 6 locations

A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)

Phase 2

Terminated

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT00000659

Locations: 🇺🇸
Tulane Univ School of Medicine, New Orleans, Louisiana, United States
🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy